Idiopathic Pulmonary Fibrosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Idiopathic Pulmonary Fibrosis (US)

Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it usually occurs in people aged 50 or older and is associated with a poor prognosis (survival of three to five years after diagnosis in most cases). Treatment can relieve the symptoms, prevent further lung scarring, and improve patients’ quality of life. Various drug classes are used to target the respective physiological mechanisms. For example, tyrosine kinase inhibitors (e.g., nintedanib [Boehringer Ingelheim’s Ofev]) block the action of enzymes that cause fibrosis, while antifibrotic agents such as pirfenidone reduce the lung fibrosis by downregulating the production of growth factors. This analysis of patient-level claims data provides insight into the dynamics of the IPF treatment landscape.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IPF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IPF patients?
• How have nintedanib and pirfenidone been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of IPF patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after diagnosis?
• What percentage of IPF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Boehringer Ingelheim, Roche / Genentech

Key drugs: Azathioprine, benralizumab, nintedanib, pirfenidone, sildenafil

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses